
Media & Press Updates
Visicell presents at California Institute of Regenerative Medicine
March 6, 2019
Visicell visited California Institute of Regenerative medicine (CIRM) and presented their recent development on non-invasive cell tracking technology. Learn more about CIRM and its patient-centered mission and impact using the link below.
Visicell is now part of Cell Therapy - TRAcking, Circulation, & Safety (CT-TRACS) Committee at HESI
February 28, 2019
Visicell had recently joined HESI CT-TRACS, a global committee with multiple stakeholders ranging from academic institutions, biotechnology/pharmaceutical companies, regulatory bodies, and other non-profit organizations across Americas, EU, and Asia. Visicell will work closely with other members of the committee such as Novartis, Beringer Manheim, Takeda, GE, Memorial Sloan Kettering, CIRM, and FDA…etc, to develop common best practices and standardize methods for evaluating the safety of cell therapy in patients
NSF I-Corps Program
November 1, 2018
Visicell team members have completed the NSF I-Corps program through the Institute of Global Entrepreneur at University of California San Diego and was awarded NSF Seed Funding for market validation.
-
We always have a story to tell, so check our news section often and contact us if you need more information!
